文献速递心脑血管急症

替奈普酶用于4.5至24小时无取栓条件的缺血性卒中

Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
PubMed 文献 · N Engl J Med · 2024-06-14
一句话结论大血管闭塞、无取栓条件且灌注成像示可挽救脑组织的缺血性卒中患者,发病4.5至24小时给予替奈普酶0.25 mg/kg(最大25 mg)较标准药物治疗提高90天无残疾比例(33.0% vs 24.2%,P=0.03),症状性颅内出血似更高(3.0% vs 0.8%),死亡相似。

TRACE-III试验在中国纳入516例大脑中动脉或颈内动脉大血管闭塞、灌注成像示可挽救脑组织、无取栓条件的缺血性卒中患者,随机接受替奈普酶0.25 mg/kg(最大25 mg)或标准药物治疗,时间窗为最后正常时间后4.5至24小时(包括醒后卒中和目击不清的卒中)。主要终点90天mRS 0-1分比例替奈普酶组33.0% vs 标准治疗组24.2%(相对率1.37,95%CI 1.04-1.81,P=0.03)。90天死亡率13.3% vs 13.1%,36小时内症状性颅内出血3.0% vs 0.8%。作者结论:替奈普酶减少残疾、生存相似,症状性颅内出血似更高。

要点

  • 适用:大脑中动脉或颈内动脉大血管闭塞、灌注成像示可挽救脑组织、无取栓条件、最后正常时间后4.5至24小时(含醒后卒中和目击不清卒中)的缺血性卒中患者。
  • 替奈普酶剂量0.25 mg/kg,最大25 mg;90天mRS 0-1分比例33.0% vs 标准治疗24.2%(相对率1.37,95%CI 1.04-1.81,P=0.03)。
  • 90天死亡率替奈普酶组13.3% vs 标准治疗组13.1%;36小时内症状性颅内出血3.0% vs 0.8%。
  • 仅不足2%患者(替奈普酶组4例、标准治疗组5例)接受补救性血管内取栓。

适用人群与场景

  • 中国患者,大脑中动脉或颈内动脉大血管闭塞,灌注成像示可挽救脑组织,无血管内取栓条件,最后正常时间后4.5至24小时(包括醒后卒中和目击不清的卒中)。

处置流程与药物剂量

  • 替奈普酶0.25 mg/kg,最大剂量25 mg,在最后正常时间后4.5至24小时给药;对照组为标准药物治疗。

研究设计与关键结果

  • 试验在中国进行,随机分配516例患者:替奈普酶组264例,标准治疗组252例。
  • 主要终点90天mRS 0-1分(无残疾)比例:替奈普酶组33.0% vs 标准治疗组24.2%(相对率1.37;95%CI 1.04-1.81;P=0.03)。
  • 90天死亡率:替奈普酶组13.3% vs 标准治疗组13.1%。
  • 36小时内症状性颅内出血发生率:替奈普酶组3.0% vs 标准治疗组0.8%。
  • 不足2%患者(替奈普酶组4例、标准治疗组5例)接受补救性血管内取栓。

证据类型、等级与局限

  • 随机对照试验(TRACE-III,ClinicalTrials.gov NCT05141305),由中华人民共和国国家自然科学基金等资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对大脑中动脉或颈内动脉大血管闭塞、灌注成像示可挽救脑组织、无取栓条件且最后正常时间后4.5至24小时的缺血性卒中患者,替奈普酶0.25 mg/kg(最大25 mg)较标准药物治疗提高90天无残疾比例,但症状性颅内出血似更高(3.0% vs 0.8%)。
  • 作者结论:替奈普酶减少残疾、生存相似,症状性颅内出血发生率似更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of tenecteplase beyond 4.5 hours are limited.

METHODS: In a trial conducted in China, we randomly assigned patients with large-vessel occlusion of the middle cerebral artery or internal carotid artery who had salvageable brain tissue as identified on perfusion imaging and who did not have access to endovascular thrombectomy to receive tenecteplase (at a dose of 0.25 mg per kilogram of body weight; maximum dose, 25 mg) or standard medical treatment 4.5 to 24 hours after the time that the patient was last known to be well (including after stroke on awakening and unwitnessed stroke). The primary outcome was the absence of disability, which was defined as a score of 0 or 1 on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability), at day 90. The key safety outcomes were symptomatic intracranial hemorrhage and death.

RESULTS: A total of 516 patients were enrolled; 264 were randomly assigned to receive tenecteplase and 252 to receive standard medical treatment. Less than 2% of the patients (4 in the tenecteplase group and 5 in the standard-treatment group) underwent rescue endovascular thrombectomy. Treatment with tenecteplase resulted in a higher percentage of patients with a modified Rankin scale score of 0 or 1 at 90 days than standard medical treatment (33.0% vs. 24.2%; relative rate, 1.37; 95% confidence interval, 1.04 to 1.81; P = 0.03). Mortality at 90 days was 13.3% with tenecteplase and 13.1% with standard medical treatment, and the incidence of symptomatic intracranial hemorrhage within 36 hours after treatment was 3.0% and 0.8%, respectively.

CONCLUSIONS: In this trial involving Chinese patients with ischemic stroke due to large-vessel occlusion, most of whom did not undergo endovascular thrombectomy, treatment with tenecteplase administered 4.5 to 24 hours after stroke onset resulted in less disability and similar survival as compared with standard medical treatment, and the incidence of symptomatic intracranial hemorrhage appeared to be higher. (Funded by the National Natural Science Foundation of China and others; TRACE-III ClinicalTrials.gov number, NCT05141305.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Xiong Y, Campbell BCV, Schwamm LH, et al. Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy. N Engl J Med. 2024. PMID: 38884324. doi:10.1056/NEJMoa2402980

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。